Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

UConn ranked top 10 for biological data research

According to CSRankings, an organization which compiles a metrics-based rankings of the top computer science programs in the world, the University of Connecticut ranks among...

| By Kelley Gipson

Cybrexa closes $13.4m B1 funding round

Cybrexa Therapeutics has completed a $13.4 million Series B1 financing. “This level of financial support from our investors demonstrates the continued enthusiasm and validation for...

| By Kelley Gipson

Shoreline Biome to Launch Product Suite

Shoreline Biome plans to unveil the market’s first end-to-end sample prep kit at the upcoming ASM Microbe 2019. The kit, Shoreline Complete, is an end-to-end...

| By Kelley Gipson

Yale studies biology of hunger hormone leptin

In a new study, Yale researchers offer insight into leptin, a hormone that plays a key role in appetite, overeating, and obesity. Their findings advance...

| By Kelley Gipson

FDA allows ReNetX Bio IND re spinal cord injury

ReNetX Bio reports that the FDA has has allowed the Company’s Investigational New Drug (IND) application for its lead drug candidate, fusion protein AXER-204. Axonal loss...

| By Kelley Gipson

FDA accepts Melinta application re BAXDELA®

Melinta Therapeutics reports that the FDA has accepted a supplemental New Drug Application for BAXDELA® (delafloxacin) for priority review. The application seeks to expand the current indication for...

| By Kelley Gipson

Alexion reports progress with ULTOMIRIS®

Alexion reports that the FDA  has accepted for priority review the company’s supplemental Biologics License Application (sBLA) for ULTOMIRIS® (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, for...

| By Kelley Gipson

CT Pavilion shines at 2019 BIO Convention

The BIO International Convention, one of the world’s largest forums for the biotech sector, welcomed a record number of attendees to Philadelphia earlier this month. Connecticut was center...

| By Kelley Gipson

SpringWorks and BeiGene form new entity, MapKure

MapKure intends to develop BGB-3245, an investigational, oral, selective small molecule inhibitor of monomer and dimer forms of activating B-RAF mutations including V600 BRAF mutations,...